Ondine Biomedical Inc. (OBIMF)

Market Cap	97.71M +93.2%
Revenue (ttm)	1.93M +34.8%
Net Income	-21.53M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.2500
Previous Close	n/a
Day's Range	0.2500 - 0.2500
52-Week Range	0.1400 - 0.2500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 21, 2026

About Ondine Biomedical

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 18
• Stock Exchange: OTCMKTS
• Ticker Symbol: OBIMF

Financial Performance

In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.

Financial numbers in CAD